Merlintrader’s Daily Briefing

Tuesday, July 21, 2026 — evening wrap. U.S. equities rallied through Tuesday’s session, with the Nasdaq leading as a rebound in chipmakers overshadowed the still-active U.S.–Iran conflict. Strong quarterly results from General Motors and 3M — both beating estimates and raising full-year guidance — set a firm tone ahead of the mega-cap earnings that dominate the rest of the week, with Alphabet and Tesla due after Wednesday’s close. Oil eased from five-week highs as Tehran signalled possible de-escalation, though a supply-risk premium lingered.

Wall Street: Tuesday’s session
  • S&P 500 — gained about 0.9%, recovering toward 7,510 after Monday’s 7,443 close, rebounding from last week’s pullback.Indices
  • Nasdaq Composite — jumped about 1.3% to roughly 25,866, the standout of the majors as semiconductors led the tape.Indices
  • Dow Jones — rose about 0.8%, or roughly 410 points, to around 52,249.Indices
  • Nasdaq 100 — was up about 2% intraday, heading for its best day in three weeks as chip names rebounded.Futures
Chip rebound led the tape
  • Memory stocks — memory-chip names sparked the rebound, dragging the broader semiconductor complex higher.AI
  • Samsung and TSMC — were lifted by strong June export data out of South Korea and Taiwan, reinforcing the AI-demand narrative.Chips
  • Context — the bounce recovered ground after a rough prior week, when the S&P 500 fell 1.6% and the Nasdaq slid 2.9% through July 18.Chips
Earnings: GM beats and raises
  • General Motors — adjusted EPS of $3.57 topped the roughly $3.13 consensus; revenue was $48.0 billion, net income $1.3 billion and EBIT-adjusted $3.9 billion.Autos
  • GM guidance — the automaker raised full-year EBIT-adjusted to $14–16 billion (adjusted EPS $12–14), up from $13.5–15.5 billion, and lifted free-cash-flow guidance to $9.5–11.5 billion.Autos
  • GM detail — a $0.18 quarterly dividend was declared; North American EBIT-adjusted rose more than 40% year over year as margins returned to the 8–10% target range.Autos
Earnings: 3M tops and lifts outlook
  • 3M — adjusted EPS of $2.40 beat the $2.24 consensus; revenue of $6.5 billion topped estimates on 5.4% adjusted organic growth.Industrials
  • 3M guidance — full-year adjusted EPS guidance was raised to $8.80–8.95, from $8.50–8.70, with the organic-growth outlook lifted above 3.5%.Industrials
  • 3M stock — shares climbed about 9% on the beat and raised outlook, among the day’s biggest large-cap movers.Industrials
Big Tech: the week’s main event
  • Alphabet and Tesla — report after Wednesday’s close; investors want proof that heavy AI capital spending is converting into revenue, with Google Cloud growth in focus.Earnings
  • Also Wednesday — IBM, Texas Instruments and AT&T round out a packed docket.Earnings
  • Thursday — Intel is a key test of the chip recovery, while Lockheed Martin serves as a defence bellwether.Defence
Oil and the Iran standoff
  • Crude — Brent held near $89 and WTI near $83, close to five-week highs, easing modestly on Tuesday.Energy
  • De-escalation hopes — Iran said mediators had submitted proposals to ease tensions, with talk of a possible 10-day ceasefire trimming the risk premium.Geopolitics
  • Supply risk — the U.S.–Iran conflict entered its 10th day, and a Houthi threat to Saudi shipping kept a floor under prices.Geopolitics
Rates and the Fed
  • Fed blackout — the Federal Reserve is in its communications quiet period before the July 29 FOMC decision.Rates
  • Data ahead — flash PMIs and the weekly jobless-claims report are the macro highlights into the earnings deluge.Macro
Biotech watch
  • Catalyst check — no specific FDA approval or PDUFA decision could be verified for today on primary sources (FDA.gov, company IR, SEC); treat any aggregator claim as unconfirmed until checked directly.Biotech
Read the full Daily Briefing
Listed / exchange-traded biotech focus

Weekly Biotech Catalyst Tracker

Window covered: July 15 → September 30, 2026. Compact homepage board for FDA decisions, advisory committees, regulatory submissions and major clinical readouts. October and later events are excluded from this widget.

38Active
20FDA / Reg
18Data / Filing
Jul 15Updated
FDA / PDUFA Clinical data Filing watch High risk Large cap
$MNKDFUROSCIX ReadyFlowJul 26sNDA Autoinjector / edema

MannKind. PDUFA for the FUROSCIX ReadyFlow autoinjector sNDA for edema in adults with chronic heart failure or chronic kidney disease.

$OTLKLYTENAVAJul 29Risk Wet AMD resubmission

Outlook Therapeutics. Class 1 resubmitted BLA PDUFA for LYTENAVA / ONS-5010 in wet AMD. Prior FDA rejection history keeps this high risk.

$CAPRderamiocel panelJul 29AdCom Panel before Aug PDUFA

Capricor. FDA advisory committee for deramiocel in Duchenne muscular dystrophy cardiomyopathy. Panel tone and briefing documents are the key pre-PDUFA read-through.

$REPLRP1 panelJul 30AdCom Melanoma panel review

Replimune. FDA advisory committee for RP1 plus nivolumab in advanced melanoma after anti-PD-1 therapy. Single-arm evidence risk remains central.

$REPLRP1Aug 2PDUFA Melanoma BLA resubmission

Replimune. BLA resubmission goal date for RP1. This is a very compressed AdCom-to-PDUFA setup with elevated regulatory risk.

$MRNAmFLUSIVAAug 5PDUFA mRNA seasonal flu

Moderna. BLA PDUFA for mRNA seasonal flu vaccine candidate in adults 50+. More platform and lifecycle read-through than pure small-cap binary.

$REGNgaretosmabAugFDA FOP ultra-rare disease

Regeneron. BLA target action month for garetosmab in adult fibrodysplasia ossificans progressiva. Month-only calendar item.

$LNTHMK-6240Aug 13NDA Tau PET imaging

Lantheus. NDA PDUFA for MK-6240 tau PET imaging in Alzheimer’s disease. Diagnostic/imaging catalyst, not a therapeutic efficacy binary.

$CAPRderamiocelAug 22PDUFA DMD cardiomyopathy

Capricor. BLA PDUFA for deramiocel in Duchenne muscular dystrophy cardiomyopathy. Prior CRL history and July AdCom make this highly binary.

$RAREDTX401Aug 23BLA GSDIa gene therapy

Ultragenyx. Priority Review BLA PDUFA for DTX401 in glycogen storage disease type Ia. First of two near-term Ultragenyx gene-therapy decisions.

$BIIBLeqembi IQLIKAug 24sBLA SC starting dose

Biogen / Eisai. sBLA PDUFA for once-weekly subcutaneous Leqembi starting-dose use. Large-cap Alzheimer’s lifecycle catalyst.

$JAZZZiihera comboAug 25sBLA 1L HER2+ GEA

Jazz Pharmaceuticals. sBLA PDUFA for Ziihera combination use in first-line HER2-positive gastroesophageal adenocarcinoma.

$GILDBIC/LENAug 27NDA Once-daily HIV regimen

Gilead. NDA PDUFA for bictegravir/lenacapavir in virologically suppressed adults. Strategic HIV franchise catalyst.

$PTGXrusfertideQ3PDUFA Polycythemia vera

Protagonist / Takeda. Priority Review NDA window for rusfertide in polycythemia vera. Exact date not pinned in this compact board.

$NUVLzidesamtinibSep 18NDA ROS1+ NSCLC

Nuvalent. NDA PDUFA for zidesamtinib in ROS1-positive non-small-cell lung cancer. Important targeted-oncology regulatory event.

$RAREUX111Sep 19Risk Sanfilippo A gene therapy

Ultragenyx. Resubmitted BLA PDUFA for UX111 in Sanfilippo syndrome type A. CMC and facility risk remain the key swing factors.

$IONSzilganersenSep 22NDA Alexander disease

Ionis. NDA PDUFA for zilganersen in Alexander disease. Rare neurological disease Priority Review event.

$BFRIAmeluz PDTSep 28sNDA Superficial BCC expansion

Biofrontera. PDUFA for Ameluz photodynamic therapy sNDA seeking expansion into superficial basal cell carcinoma. Small-cap liquidity can amplify reaction.

$SRRKapitegromabSep 30BLA Spinal muscular atrophy

Scholar Rock. BLA PDUFA for apitegromab in spinal muscular atrophy. Manufacturing and fill-finish facility status remain key watch items.

$ROIVbrepocitinibQ3NDA Dermatomyositis

Priovant / Roivant. NDA Priority Review window for brepocitinib in dermatomyositis. Company has pointed to potential launch timing by end-September if approved.

$QUREAMT-130Q3BLA Huntington’s AA path

uniQure. Planned BLA submission for AMT-130 in Huntington’s disease. Not a PDUFA, but one of the most important regulatory-pathway events in the quarter.

$SLNdivesiranAugData SANRECO Phase 2 PV

Silence Therapeutics. SANRECO Phase 2 topline data for divesiran in polycythemia vera. Important read-through alongside $PTGX / Takeda rusfertide.

$IMMXNXC-201Q3Data AL amyloidosis

Immix Biopharma. NEXICART-2 topline data for NXC-201 in relapsed/refractory AL amyloidosis. BLA-enabling study, high-volatility small-cap setup.

$KPTIselinexorNearData Endometrial cancer Ph3

Karyopharm. XPORT-EC-042 Phase 3 topline data for selinexor in endometrial cancer. Treat as near-term until released or formally delayed.

$KODDAYBREAKQ3Data Wet AMD Phase 3

Kodiak Sciences. DAYBREAK Phase 3 topline data for tarcocimab / KSI-501 in wet AMD. Watch efficacy, durability, dosing interval and safety.

$ALMSenvudeucitinibQ3Data SLE Phase 2b

Alumis. LUMUS Phase 2b readout for envudeucitinib in systemic lupus erythematosus. Autoimmune data can be noisy; dose response matters.

$IVVDVYD2311Q3Data DECLARATION pivotal

Invivyd. DECLARATION pivotal / Phase 3 topline data for VYD2311. COVID-antibody sentiment can be unstable, but pivotal data can still move the name.

$MPLTML-007C-MAMid-AugData ZEPHYR schizophrenia Ph2

MapLight Therapeutics. Phase 2 ZEPHYR topline results for ML-007C-MA in schizophrenia. CNS readout with potentially sharp binary reaction.

$AMLXavexitideQ3Ph3 PBH pivotal LUCIDITY

Amylyx. Phase 3 LUCIDITY topline results for avexitide in post-bariatric hypoglycemia. One of the clearest Phase 3 clinical binaries of the quarter.

$PHVSdeucrictibant ERQ3Ph3 HAE prophylaxis Ph3

Pharvaris. Phase 3 CHAPTER-3 data for extended-release deucrictibant as prophylaxis for hereditary angioedema. Major HAE readout.

$SYRESPY003Q3Data IBD / UC Phase 2

Spyre Therapeutics. Phase 2 SKYLINE Part A topline data for SPY003 in inflammatory bowel disease and ulcerative colitis.

$VERATrutakna / ataciceptQ3eGFR ORIGIN 3 follow-up

Vera Therapeutics. ORIGIN 3 eGFR analysis following accelerated approval. Not another approval decision, but important for durability and confirmatory confidence.

$OCGNOCU410STQ3Data Stargardt interim analysis

Ocugen. Interim OCU410ST analysis after 24 patients complete eight months of follow-up in Stargardt disease. Small-cap ophthalmology catalyst.

$XENEazetukalnerQ3NDA Focal-onset seizures filing

Xenon. Expected NDA submission for azetukalner in focal-onset seizures. Filing confirmation would set up future FDA acceptance and PDUFA timing.

$BBIOinfigratinibQ3NDA Achondroplasia filing

BridgeBio. Expected NDA submission for infigratinib in achondroplasia. Submission timing and acceptance will define the next regulatory leg.

$CLNNCNM-Au8Q3NDA ALS accelerated pathway

Clene. Targeted NDA submission for CNM-Au8 in ALS through an accelerated pathway. Very high regulatory strategy risk because submission does not guarantee acceptance.

$OCGNOCU400Q3BLA Rolling BLA start

Ocugen. Expected start of rolling BLA submission for OCU400 in retinitis pigmentosa. Filing progress, manufacturing and future acceptance are the next watch items.

$MLTXsonelokimabLate SepBLA HS filing watch

MoonLake. Planned BLA submission for sonelokimab in hidradenitis suppurativa around the end of September. Acceptance would create the next formal FDA calendar item.

Most attention-worthy watchlist

$OTLK$REPL$CAPR$RARE$NUVL$IONS$SRRK$AMLX$PHVS$QURE$MPLT

Board rule

Only July–September catalysts are shown. October and later events are intentionally excluded from this compact homepage widget. Resolved decisions are removed from the active board: $CELC Revtorpyk / gedatolisib was approved by the FDA on July 14, ahead of its July 17 PDUFA date, with the U.S. commercial launch expected in Q3 2026; $SNY Sarclisa SC was approved on July 10, ahead of its original July 23 target date. Events with only Q3 guidance are included, but should be rechecked against company filings before trading around them.

Educational content only — not investment advice. Verify dates and filings before trading around binary events. Full catalyst calendar FDA SEC EDGAR

Biotech Catalyst Lookup

Type a ticker to get an AI-generated snapshot of the next catalyst (PDUFA, clinical data, regulatory events) with a link to the primary source.

Disclaimer. This content is for educational and informational purposes only. It is not investment advice and not a recommendation to buy or sell any security, in line with CONSOB (Italy) and SEC (USA) guidance. Data is generated by AI from web sources and may contain errors or be out of date — always verify against the linked primary source. Do your own research and consult a licensed advisor. Full disclaimer: merlintrader.com/disclaimer.

Avvertenza. Questo contenuto ha finalità esclusivamente didattiche e informative. Non costituisce consulenza finanziaria né una raccomandazione di acquisto o vendita di alcun titolo, in linea con le indicazioni CONSOB (Italia) e SEC (USA). I dati sono generati dall'AI a partire da fonti web e possono contenere errori o non essere aggiornati — verifica sempre rispetto alla fonte primaria collegata. Fai le tue ricerche e consulta un consulente autorizzato. Disclaimer completo: merlintrader.com/disclaimer.